Core Viewpoint - Haikou, as the core area of Hainan Free Trade Port, has shown significant progress during the "14th Five-Year Plan" and is now focusing on a development blueprint of "six cities" for the "15th Five-Year Plan" to enhance its international perspective, industrial resilience, and cultural warmth [1][2]. Group 1: Economic Development - During the "14th Five-Year Plan," Haikou's actual foreign investment and overseas direct investment grew at an average annual rate of 12.6% and 55.2%, respectively, while the total import and export volume of goods and services increased by 20.2% and 18% annually [1]. - The implementation of 39 core policies of the Hainan Free Trade Port in Haikou has led to a cumulative declaration of 66 enterprises under the zero-tariff policy, with an internal sales value of 1.6 billion yuan [1]. Group 2: Infrastructure and Connectivity - Haikou plans to attract global headquarters enterprises and enhance domestic companies' overseas layouts, alongside expanding Meilan International Airport's third phase to increase domestic and international direct flight routes [2]. - The city aims to strengthen cooperation with the Guangdong-Hong Kong-Macao Greater Bay Area and deepen collaboration with regions like Beijing-Tianjin-Hebei and the Yangtze River Delta [2]. Group 3: Industry and Innovation - Haikou will focus on developing a modern industrial system with local characteristics, emphasizing innovation in pharmaceuticals and digital services, including game exports and cross-border live streaming [4][5]. - The city plans to cultivate a leasing economy centered on aircraft, ships, and specialized equipment, while promoting the full-chain development of the electronic information industry [4]. Group 4: Consumer and Cultural Development - Haikou aims to enhance consumer vitality by hosting large-scale events and attracting renowned brands, while leveraging the effects of the offshore duty-free policy [7]. - The city plans to develop its cultural industry by protecting historical sites and promoting cultural exchange, alongside fostering new industries like gaming and digital culture [9]. Group 5: Environmental and Social Initiatives - Haikou is committed to green transformation through projects aimed at ecological protection and climate adaptation, striving to build a "cool city" system [7]. - The city focuses on improving living standards by creating a job-friendly environment and optimizing educational resources, ensuring that development benefits all citizens [7].

报告期内，公司依托全流程研发平台的核心竞争力，持续加大市场开拓力度，获取订单能力进一步提升，带动主营业务收 入增长。同时，公司深入推进降本增效举措，持续优化成本管控与资源配置结构，预计期间费用同比有所下降，盈利水平有效 提升。 （编辑 张明富） 本报讯 （记者李雯珊 见习记者张美娜）近日，睿智医药科技股份有限公司（以下简称"睿智医药"）披露公告，2025年， 公司预计实现归属于上市公司股东的净利润1230万元至1845万元，较上年同期扭亏为盈。 根据公告，报告期内，公司实施股权激励计划，较上年同期新增股权激励费用，若剔除股权激励费用摊销的影响（不考虑 所得税影响），则预计2025年实现归属于上市公司股东的净利润6630万元至7245万元。 ...

IP-SAFE项目依托近代物理所在强流超导直线加速器、高功率靶和同位素分离等领域的技术积累和优势，旨在实现全球紧缺的医用阿尔法同位素—— 锕-225、镭-223的规模化生产，着力破解我国此类高端医用核素长期依赖进口的局面。 该项目是以超导直线加速器为基础来做阿尔法同位素靶向药的研发平台。超导直线加速器产生质子，轰击靶材产出阿尔法同位素，再将这些同位素做成靶向 药物，就能精准"找到"癌细胞，释放射线杀死癌细胞，对周围正常细胞伤害小。这个平台就是帮科学家解决靶向药物同位素原料的来源问题。项目2024年7 月5日正式启动建设。基于加速器的医用同位素药物研发平台全面建成后，将有力提升我国核医学诊疗水平，为我国生物医药产业的发展注入新的动力。 记者从中国科学院近代物理研究所（以下简称"近代物理所"）获悉，2月2日，该研究所负责建设的"基于加速器的医用同位素药物研发平台"（IP-SAFE项 目）取得新进展，其加速器装置主体顺利完成现场安装。这标志着国际首台基于超导直线加速器的阿尔法医用同位素量产示范装置建设向前迈出最重要一 步。 ...

（来源：中科院之声） 临床研究显示，经典致幻剂如麦角酸二乙酰胺（LSD）、裸盖菇素（psilocybin）等，在治疗重度抑郁症、难治性抑郁及焦虑相关疾病方面展现出显著疗 效，但其致幻副作用始终是阻碍其临床转化的主要障碍。传统理论将5-HT2A受体激活后的Gq信号通路过度激活视为致幻主因，这一观点难以完全解释致 幻剂的复杂药理特性。 ▲靶向5-HT2A受体的致幻剂 及非致幻类似物的药理学特征。 中国科学院长春应用化学研究所等合作，系统表征了5-HT2A受体激活后触发的下游信号级联反应，首次确证Gi信号通路在致幻剂作用中的关键功能，揭 示了经典致幻剂作用的新机制。 基于这一分子机制，研究团队通过理性药物设计，开发出新型5-HT2AR选择性Gq偏好性激动剂DOI-NBOMe。在临床前模型中，DOI-NBOMe展现出类抗 焦虑和类抗抑郁功效，却未诱发致幻样效应，实现了致幻剂的治疗效益与致幻副作用的有效分离。 ▲Gq偏好性激动剂DOI-NBOMe在动物模型中展现类抗焦虑与抗抑郁作用，同时未检测到致幻样效应。 该研究为理解致幻剂的作用机制提供了全新理论框架，开创了基于受体信号偏好性进行精准药物设计的新范式，为开发新一代非 ...

Investment Rating - The report maintains a positive outlook on the overseas education sector, particularly highlighting key companies in the education and training industry [1]. Core Insights - The overseas education sector has shown significant improvement in operational efficiency, with a focus on key companies in the education and training industry [1]. - New Oriental (09901.HK) reported a revenue of $1.191 billion for Q2 FY26, a year-on-year increase of 14.7%, with a Non-GAAP net profit of $73 million, reflecting a 68.6% increase [6]. - Oriental Selection (01797.HK) achieved a revenue of 2.31 billion yuan in 1H FY26, up 5.7% year-on-year, and turned a profit with a net profit of 239 million yuan [9]. Summary by Sections 1. Overseas Education - The education index surged by 7.2% in the week of January 23-29, outperforming the Hang Seng Index by 2.2 percentage points [5]. - New Oriental's education business (including cultural tourism) generated $974 million, a 13% increase year-on-year, while other businesses (mainly Oriental Selection) saw a 22.9% revenue growth [6]. - The study abroad business's revenue growth has stabilized, with a 1% increase year-on-year, although it has slowed compared to previous periods [6]. 2. Oriental Selection - The company reported a revenue of 2.31 billion yuan in 1H FY26, marking a 5.7% increase year-on-year, and achieved profitability with a net profit of 239 million yuan [9]. - The gross merchandise volume (GMV) from self-operated products reached 2.16 billion yuan, with a significant improvement in gross margin from 21.5% to 33.7% year-on-year [10]. - The company is expanding its product offerings and enhancing operational efficiency, with a focus on increasing the utilization rate of existing teaching sites [7]. 3. Overseas Pharmaceuticals - The report highlights a strategic R&D collaboration between CSPC Pharmaceutical Group and AstraZeneca, valued at $18.5 billion, focusing on innovative long-acting peptide drugs [3][19]. - The agreement includes a $1.2 billion upfront payment and potential milestone payments totaling up to $13.8 billion, along with sales royalties based on net sales [19]. 4. Overseas Social Services - Macau's gaming revenue maintained double-digit growth, with December's gross gaming revenue reaching 20.9 billion MOP, a 14.8% year-on-year increase [23]. - The total visitor count for Macau in 2025 reached 40.06 million, a 14.7% increase year-on-year, marking a historical high [23].

Group 1: Key Insights - The report highlights multiple positive catalysts for the electronics sector, particularly for Huadian Co., Ltd. (002463), including the upcoming financial disclosures from overseas cloud vendors and domestic supply chain performance forecasts, which will validate the sustainability of computing power demand and industry prosperity [4] - The defense and military industry, represented by Guoke Military Industry (688543), is transitioning from conventional ammunition to intelligent and information-based ammunition, positioning the company to benefit from high industry demand and military trade orders, which are expected to drive significant growth [4] - In the pharmaceutical and biotechnology sector, Huan Huang Pharmaceutical (0013.HK) is advancing its ATTC platform with candidates entering clinical trials, including HMPL-A251, which is a first-in-class drug, and is also expanding the indications for existing drugs, indicating strong future growth potential [5] Group 2: Company-Specific Analysis - Wan Hua Chemical (600309) is reinforcing its position as a global leader in polyurethane, with significant market shares in MDI and TDI, and is expected to enhance profitability through strategic partnerships and cost advantages in its petrochemical segment [6] - Su Kan Agricultural Development (601952) anticipates a slight decline in 2025 profits due to falling grain prices, but expects a recovery driven by rising grain prices and increased farmland area through land transfer initiatives [7] - Yingwei Technology (002837) is poised for substantial growth in the server liquid cooling market, with expectations of doubling industry growth in 2026 and 2027, supported by orders from major overseas clients [8] Group 3: Financial Performance and Projections - China Pacific Insurance (601601) demonstrated strong resilience with a 11% year-on-year increase in net profit to 27.9 billion yuan, driven by robust growth in new business value in its life insurance segment [8] - Jin Jiang Shipping (601083) reported a 64% year-on-year increase in net profit for Q3, indicating strong performance relative to peers, with expectations for continued growth [8] - Xiaoshangcheng (600415) is benefiting from increased rental income and new merchant additions, with projections for profit doubling in 2026 due to enhanced service offerings and improved gross margins [8]

Core Viewpoint - Sunshine Nuohuo (688621.SH) has officially terminated its plan to acquire 100% equity of Langyan Life, marking the second failed attempt since 2022, amid challenges from policy changes and valuation disputes [1][3]. Group 1: Acquisition Attempts - The first acquisition attempt in 2022 was priced at 1.611 billion yuan, while the second attempt in 2025 was reduced to 1.2 billion yuan, a 25.5% decrease [2][4]. - The core products of Langyan Life, including Valsartan and Entecavir, faced significant price reductions due to centralized procurement, impacting revenue and profit forecasts [3][4]. - The termination of the first acquisition occurred on August 1, 2023, and the second on January 27, 2026, with both attempts facing scrutiny from the Shanghai Stock Exchange [2][5]. Group 2: Financial Performance and Market Conditions - Langyan Life's revenue dropped from 617 million yuan in 2022 to 465 million yuan in 2023, with net profit falling from approximately 80 million yuan to 36.71 million yuan [3][4]. - The company set a performance commitment for the second acquisition, requiring a cumulative net profit of at least 404 million yuan from 2025 to 2028 [2][4]. - Despite a report suggesting opportunities from a shift towards quality in procurement policies, market skepticism regarding the sustainability of Langyan Life's profitability persisted [5][6]. Group 3: Regulatory and Advisory Context - Guolian Minsheng Securities served as the independent financial advisor for both acquisition attempts, facing challenges in transaction structuring and compliance due to market conditions [6][8]. - The Shanghai Stock Exchange raised multiple inquiries regarding the fairness of pricing and the feasibility of performance commitments during the second acquisition attempt [4][5]. - Sunshine Nuohuo stated that the termination of the acquisition would not significantly impact its operational and financial status, projecting a revenue increase of 10.57% to 27.15% for 2025 [7][8].

Core Viewpoint - The company plans to establish a wholly-owned subsidiary, Zhejiang Xupei Pharmaceutical Technology Co., Ltd., with an investment of 58.4994 million yuan (excluding tax) for land use rights and construction projects [1] Group 1: Investment Details - The investment will be funded entirely by the company's own assets, with a contribution ratio of 100% [1] - The registered capital of the new subsidiary will be 10 million yuan, located in Linping District, Hangzhou, Zhejiang Province [1] Group 2: Strategic Objectives - The purpose of establishing the new company is to enrich the research and development sector, optimize business layout and management structure, enhance core competitiveness, and improve sustainable development capabilities [1] Group 3: Corporate Governance - The investment decision has been approved by the company's fourth board of directors' ninth meeting and does not require submission to the shareholders' meeting [1] - The investment does not constitute a major asset restructuring and does not involve related party transactions [1] Group 4: Financial Impact - The company anticipates that this investment will not have a significant adverse impact on its financial and operational status, nor will it harm the interests of the listed company and its shareholders [1]

Group 1 - The company held its first extraordinary board meeting of 2026 on January 28, 2026, with all five directors present, and the meeting complied with relevant laws and regulations [2][3][24] - The board approved a financial assistance proposal where the company and an affiliate, Hainan Zhijian Pharmaceutical Co., Ltd., will provide a total of up to RMB 120 million to its subsidiary, Zhongshan Runle Pharmaceutical Co., Ltd., with the company contributing up to RMB 40 million [12][13][14] - The financial assistance is intended to support Zhongshan Runle's working capital needs and debt repayment, with a loan term of two years at an interest rate of 3% [12][13][20] Group 2 - The board's decision on the financial assistance will be submitted to the shareholders' meeting for approval, with related parties abstaining from voting [5][25][34] - The company has not previously provided financial assistance to Zhongshan Runle, and the total financial assistance balance before this announcement was zero [19][26] - The independent directors reviewed and approved the financial assistance proposal, stating it aligns with Zhongshan Runle's operational needs and does not adversely affect the company's normal operations [23][24] Group 3 - The company will hold its first extraordinary shareholders' meeting on February 13, 2026, to discuss the approved financial assistance proposal [30][31][34] - The meeting will allow for both on-site and online voting, with specific timeframes for participation [31][37] - Shareholders must register by February 6, 2026, to attend the meeting, and the meeting will take place at the company's headquarters [33][36]

【国信医药】阳光诺和终止发行股份及可转债全资收购江苏朗研事项 1时间线：2025年4月25日筹划发行并停牌，2025年9月26日首次披露重组草案，2025年11月1日提交问询函回 复，2025年11月18日收到交易所受理通知，2025年11月28日收到审核问询函，2026年1月27日董事会正式通过终止 议案 2近日，公司发布2025年业绩预告，2025年预计实现营业收入11.92-13.71亿元，同比增长10.57%–27.15%；归母 净利润为1.91-2.29亿元，同比增长7.69%–29.23%；扣非净利润1.80-2.16亿元，同比增长8.84%–30.61%。 【国信医药】阳光诺和终止发行股份及可转债全资收购江苏朗研事项 1时间线：2025年4月25日筹划发行并停牌，2025年9月26日首次披露重组草案，2025年11月1日提交问询函回 复，2025年11月18日收到交易所受理通知，2025年11月28日收到审核问询函，2026年1月27日董事会正式通过终止 议案 2近日，公司发布2025年业绩预告，2025年预计实现营业收入11.92-13.71亿元，同比增长 ...